



ASX Announcement

Sunshine Heart appoints CRO for US clinical trial: Alquest, Inc.

Sydney, 29 March 2007: Sunshine Heart (ASX: SHC) has appointed US clinical experts, Alquest Inc, to fast track the commencement of the multi-centre feasibility trial of the C-Pulse™ implantable heart assist device in North America.

Alquest is an internationally respected Contract Research Organization (CRO) specializing in medical devices. Alquest will work closely with Sunshine Heart's US-based clinical team to establish and monitor trials of the C-Pulse™ device in a number of large prestigious university based hospitals and regional referral hospitals.

Alquest will assist Sunshine Heart's US clinical trial team, including two recently appointed co-principal investigators, to manage the C-Pulse™ trials in the roles of site activation, clinical monitoring, data management and statistical analysis.

"We are confident that Alquest will provide the extensive clinical expertise required to commence the C-Pulse™ trial in the US later this year" said Ms Mary Beth Kepler, Sunshine Heart's US Clinical Director.

Alquest's extensive cardiovascular medical device experience, along with their personal experiences gained from the international medical device companies in the Minneapolis area, uniquely qualified Alquest to complement Sunshine Heart's clinical team.

President of Alquest, Ms Ann Quinlan-Smith, said "We look forward to assisting Sunshine Heart in achieving regulatory approval in a timely and quality fashion."

"The C-Pulse™ clinical experience gained in the current Australian/ New Zealand pilot trial provides a foundation for the US Feasibility trial" said Mr Donald Rohrbaugh, Chief Executive Officer of Sunshine Heart, Inc.

About Alquest, Inc

Based in the Minneapolis, Alquest, Inc is an internationally respected contract research organization which specializes in medical devices. Alquest has assisted more than 300 medical device firms including Fortune 100 companies with the design and execution of feasibility, pivotal and post-market clinical trials (www.alquest.com).

About Sunshine Heart

Sunshine Heart (ASX: SHC) is a global medical device company committed to the commercialization of the C-Pulse™, an implantable, non-blood contacting, mechanical heart assist device for the treatment of people with heart failure. Sunshine Heart listed on the ASX in September 2004 and has a presence in Australia, New Zealand and the United States of America.

More information about the C-Pulse™ heart assist device may be obtained at www.sunshineheart.com

For further information, please contact:

Media Daniella Goldberg PhD +612 9237 2803 / 0416 211 067 dgoldberg@bcg.com.au Alquest Tom Huyck Business Development +1 763 287 3830 customercare@alquest.com	Sunshine Heart Victor Windeyer COO +61 2 8424 7713 Victor.windeyer@sunshineheart.com Don Rohrbaugh CEO +1 714 665 1951 don.rohrbaugh@sunshineheart.com
--	---